vs
Side-by-side financial comparison of Caledonia Mining Corp Plc (CMCL) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $46.9M, roughly 1.9× Caledonia Mining Corp Plc). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 13.8%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 17.1%).
Hochschild Mining plc is a leading British-based silver and gold mining business operating in North, Central, and South America. It is headquartered in Lima, Peru, with a corporate office in London, is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The main shareholder is the Peruvian businessman Eduardo Hochschild.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CMCL vs IOVA — Head-to-Head
Income Statement — Q3 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $46.9M | $86.8M |
| Net Profit | $3.3M | — |
| Gross Margin | 41.2% | 67.4% |
| Operating Margin | 18.6% | -84.7% |
| Net Margin | 7.0% | — |
| Revenue YoY | 13.8% | 17.7% |
| Net Profit YoY | -33.3% | — |
| EPS (diluted) | $0.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $86.8M | ||
| Q3 25 | — | $67.5M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $49.3M | ||
| Q4 24 | — | $73.7M | ||
| Q3 24 | $46.9M | $58.6M | ||
| Q2 24 | $50.1M | $31.1M | ||
| Q1 24 | $38.5M | $715.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-91.3M | ||
| Q2 25 | — | $-111.7M | ||
| Q1 25 | — | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.3M | $-83.5M | ||
| Q2 24 | $10.2M | $-97.1M | ||
| Q1 24 | $2.1M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | 41.2% | 46.2% | ||
| Q2 24 | 45.8% | -0.8% | ||
| Q1 24 | 35.9% | — |
| Q4 25 | — | -84.7% | ||
| Q3 25 | — | -140.7% | ||
| Q2 25 | — | -189.8% | ||
| Q1 25 | — | -245.8% | ||
| Q4 24 | — | -117.5% | ||
| Q3 24 | 18.6% | -152.1% | ||
| Q2 24 | 32.2% | -327.6% | ||
| Q1 24 | 13.8% | -16464.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | -135.3% | ||
| Q2 25 | — | -186.2% | ||
| Q1 25 | — | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 7.0% | -142.7% | ||
| Q2 24 | 20.3% | -312.2% | ||
| Q1 24 | 5.4% | -15800.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.33 | ||
| Q1 25 | — | $-0.36 | ||
| Q4 24 | — | $-0.24 | ||
| Q3 24 | $0.13 | $-0.28 | ||
| Q2 24 | $0.42 | $-0.34 | ||
| Q1 24 | $0.07 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.2M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $231.0M | $698.6M |
| Total Assets | $339.7M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | $7.2M | $397.5M | ||
| Q2 24 | $15.4M | $412.5M | ||
| Q1 24 | $1.8M | $356.2M |
| Q4 25 | — | $698.6M | ||
| Q3 25 | — | $702.3M | ||
| Q2 25 | — | $698.5M | ||
| Q1 25 | — | $767.9M | ||
| Q4 24 | — | $710.4M | ||
| Q3 24 | $231.0M | $773.5M | ||
| Q2 24 | $231.1M | $768.5M | ||
| Q1 24 | $220.3M | $680.0M |
| Q4 25 | — | $913.2M | ||
| Q3 25 | — | $904.9M | ||
| Q2 25 | — | $907.4M | ||
| Q1 25 | — | $966.7M | ||
| Q4 24 | — | $910.4M | ||
| Q3 24 | $339.7M | $991.1M | ||
| Q2 24 | $338.5M | $964.3M | ||
| Q1 24 | $321.8M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.6M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | 1.40× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-52.6M | ||
| Q3 25 | — | $-78.7M | ||
| Q2 25 | — | $-67.4M | ||
| Q1 25 | — | $-103.7M | ||
| Q4 24 | — | $-73.3M | ||
| Q3 24 | $4.6M | $-59.0M | ||
| Q2 24 | $19.1M | $-98.4M | ||
| Q1 24 | — | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMCL
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
